Datapoint: Gilead Scores Broader Breast Cancer Nod for Trodelvy
The FDA last week approved Gilead Sciences’ Trodelvy for the treatment of HR-positive, HER2-negative breast cancer in patients whose cancer has not responded to three previous therapies, including endocrine therapy. The nod will make Trodelvy available to a broader patient group, as a majority of breast cancer patients have the HR-positive, HER2-negative form of the disease. Trodelvy is already approved to treat triple-negative breast cancer, an indication for which it holds covered or better status for 91% of all insured lives under the medical benefit.
SOURCE: MMIT Analytics, as of 2/6/23